Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry

M. Fishman; J. P. Dutcher; J. I. Clark; A. Alva; G. P. Miletello; B. Curti; Neeraj Agarwal; R. Hauke; K. M. Mahoney; H. Moon; J. Treisman; S. S. Tykodi; G. Daniels; M. A. Morse; M. K. K. Wong; H. Kaufman; N. Gregory; D. F. McDermott

doi:10.1186/s40425-019-0567-3

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF

XML

Research Article

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM^SM registry

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Fishman M, Dutcher JP, Clark JI, et al

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM^SM registry

Journal for ImmunoTherapy of Cancer 2019;7:84. doi: 10.1186/s40425-019-0567-3

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password